Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro

Han,Jang Mi; Kwon,Ho Jeong; Jung,Hye Jin

doi:10.3892/ijo.2016.3645

Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro

Authors:
- Jang Mi Han
- Ho Jeong Kwon
- Hye Jin Jung
View Affiliations

Affiliations: Department of BT-Convergent Pharmaceutical Engineering, Sun Moon University, Chungnam 336-708, Republic of Korea, Department of Biotechnology, Yonsei University, Seodaemun-gu, Seoul 120-749, Republic of Korea
Published online on: August 3, 2016 https://doi.org/10.3892/ijo.2016.3645
Pages: 1497-1504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor growth and metastasis depend on angiogenesis triggered by chemical signals, such as vascular endothelial growth factor (VEGF), released from tumor cells. Therefore, the specific perturbation of angiogenesis has been considered a powerful strategy for the treatment of cancer. Herein, we report that tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro. Tricin effectively suppressed the proliferation as well as VEGF-induced invasion and tube formation of human umbilical vein endothelial cells (HUVECs) at subtoxic doses. Furthermore, tricin significantly inhibited the angiogenesis of the chorioallantoic membrane from growing chick embryos without showing cytotoxicity. We also found that tricin blocked tumor cell-induced angiogenesis. Notably, tricin downregulated not only the VEGFR2 signal transduction by reducing reactive oxygen species (ROS) generation in endothelial cells, but also the expression of VEGF by inhibiting hypoxia inducible factor-1α (HIF-1α) accumulation in tumor cells. Moreover, combined treatment with tricin and bevacizumab, an anti-VEGF drug, ameliorated the antiangiogenic effect of bevacizumab. Taken together, our findings demonstrate for the first time that tricin possesses promising antiangiogenic potential and thus may be applied to anticancer therapy by targeting tumor angiogenesis.

View Figures

View References

1	Bussolino F, Mantovani A and Persico G: Molecular mechanisms of blood vessel formation. Trends Biochem Sci. 22:251–256. 1997. View Article : Google Scholar : PubMed/NCBI
2	Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
3	Carmeliet P: Angiogenesis in health and disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
4	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
5	André T, Chastre E, Kotelevets L, Vaillant JC, Louvet C, Balosso J, Le Gall E, Prévot S and Gespach C: Tumoral angiogenesis: Physiopathology, prognostic value and therapeutic perspectives. Rev Med Interne. 19:904–913. 1998.(In French). View Article : Google Scholar
6	Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
7	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
8	Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 19:2003–2012. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ivy SP, Wick JY and Kaufman BM: An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 6:569–579. 2009. View Article : Google Scholar : PubMed/NCBI
11	Chen HX and Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
12	Verheul HM and Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI
13	Höckel M and Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
14	Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
15	Semenza GL: HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 8(Suppl): S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
16	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
17	Harborne JB: Nature, distribution and function of plant flavonoids. Prog Clin Biol Res. 213:15–24. 1986.PubMed/NCBI
18	Havsteen BH: The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 96:67–202. 2002. View Article : Google Scholar : PubMed/NCBI
19	Cai H, Hudson EA, Mann P, Verschoyle RD, Greaves P, Manson MM, Steward WP and Gescher AJ: Growth-inhibitory and cell cycle-arresting properties of the rice bran constituent tricin in human-derived breast cancer cells in vitro and in nude mice in vivo. Br J Cancer. 91:1364–1371. 2004. View Article : Google Scholar : PubMed/NCBI
20	Hudson EA, Dinh PA, Kokubun T, Simmonds MS and Gescher A: Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev. 9:1163–1170. 2000.PubMed/NCBI
21	Oyama T, Yasui Y, Sugie S, Koketsu M, Watanabe K and Tanaka T: Dietary tricin suppresses inflammation-related colon carcinogenesis in male Crj: CD-1 mice. Cancer Prev Res (Phila). 2:1031–1038. 2009. View Article : Google Scholar
22	Ali MA, Choy H, Habib AA and Saha D: SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 9:370–381. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ushio-Fukai M: VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal. 9:731–739. 2007. View Article : Google Scholar : PubMed/NCBI
24	Jung HJ, Kim Y, Chang J, Kang SW, Kim JH and Kwon HJ: Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells. J Mol Med (Berl). 91:1117–1128. 2013. View Article : Google Scholar
25	Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008. View Article : Google Scholar : PubMed/NCBI
26	El-Kenawi AE and El-Remessy AB: Angiogenesis inhibitors in cancer therapy: Mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 170:712–729. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhou J and Ibrahim RK: Tricin - a potential multifunctional nutraceutical. Phytochem Rev. 9:413–424. 2010. View Article : Google Scholar
28	Shalini V, Pushpan CK, Sindhu G, Jayalekshmi A and Helen A: Tricin, flavonoid from Njavara reduces inflammatory responses in hPBMCs by modulating the p38MAPK and PI3K/Akt pathways and prevents inflammation associated endothelial dysfunction in HUVECs. Immunobiology. 221:137–144. 2016. View Article : Google Scholar
29	Shalini V, Jayalekshmi A and Helen A: Mechanism of anti-inflammatory effect of tricin, a flavonoid isolated from Njavara rice bran in LPS induced hPBMCs and carrageenan induced rats. Mol Immunol. 66:229–239. 2015. View Article : Google Scholar : PubMed/NCBI
30	Cai H, Al-Fayez M, Tunstall RG, Platton S, Greaves P, Steward WP and Gescher AJ: The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice. Mol Cancer Ther. 4:1287–1292. 2005. View Article : Google Scholar : PubMed/NCBI
31	Jeong YH, Chung SY, Han AR, Sung MK, Jang DS, Lee J, Kwon Y, Lee HJ and Seo EK: P-glycoprotein inhibitory activity of two phenolic compounds, (−)-syringaresinol and tricin from Sasa borealis. Chem Biodivers. 4:12–16. 2007. View Article : Google Scholar : PubMed/NCBI
32	Cai H, Boocock DJ, Steward WP and Gescher AJ: Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol. 60:257–266. 2007. View Article : Google Scholar
33	Verschoyle RD, Greaves P, Cai H, Borkhardt A, Broggini M, D’Incalci M, Riccio E, Doppalapudi R, Kapetanovic IM, Steward WP, et al: Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemother Pharmacol. 57:1–6. 2006. View Article : Google Scholar